☰

Morvarid Mohseni, Ph.D - Publications

Affiliations: 
2009-2013 Stem Cell & Regenerative Biology Harvard - Boston Children's Hospital 
Area:
Cell Biology, Oncology, Regenerative Biology, Molecular Pharmacology, Stem Cell Biology,
Tree Info Grants Similar researchers PubMed Report error

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Amante RJ, Jehanno C, De Silva D, Coissieux MM, Ackerknecht M, Romanet V, Sethi A, Hamelin B, Preca BT, Piscuoglio S, Ng CKY, Mohseni M, Bentires-Alj M. PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer. Journal of Mammary Gland Biology and Neoplasia. 28: 13. PMID 37294349 DOI: 10.1007/s10911-023-09539-9  0.417
2021 Vemulapalli V, Chylek LA, Erickson A, Pfeiffer A, Gabriel KH, LaRochelle J, Subramanian K, Cao R, Stegmaier K, Mohseni M, LaMarche MJ, Acker MG, Sorger PK, Gygi SP, Blacklow SC. Time resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling. Elife. 10. PMID 33755016 DOI: 10.7554/eLife.64251  0.616
2021 Wang Y, Mohseni M, Grauel A, Diez JE, Guan W, Liang S, Choi JE, Pu M, Chen D, Laszewski T, Schwartz S, Gu J, Mansur L, Burks T, Brodeur L, et al. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Scientific Reports. 11: 1399. PMID 33446805 DOI: 10.1038/s41598-021-80999-x  0.71
2020 Hao HX, Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G, Kowal C, Delach S, Wang Y, Goldoni S, Hastings WD, Wong K, Gao H, Meyer MJ, ... ... Mohseni M, et al. Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33046519 DOI: 10.1158/1078-0432.CCR-20-2718  0.427
2020 LaMarche MJ, Acker MG, Argintaru A, Bauer D, Boisclair J, Chan H, Chen C, Chen YP, Chen Z, Deng Z, Doré M, Dunstan D, Fan J, Fekkes P, Firestone B, ... ... Mohseni M, et al. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry. PMID 32910655 DOI: 10.1021/Acs.Jmedchem.0C01170  0.498
2020 Lu H, Liu C, Huynh H, Le TBU, LaMarche MJ, Mohseni M, Engelman JA, Hammerman PS, Caponigro G, Hao HX. Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. Oncotarget. 11: 265-281. PMID 32076487 DOI: 10.18632/Oncotarget.27435  0.521
2019 Pandey R, Ramdas B, Wan C, Sandusky G, Mohseni M, Zhang C, Kapur R. SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations. The Journal of Clinical Investigation. PMID 31682240 DOI: 10.1172/Jci130520  0.61
2019 Hao HX, Wang H, Liu C, Kovats S, Velazquez R, Lu H, Pant B, Shirley M, Meyer MJ, Pu M, Lim J, Fleming M, Alexander L, Farsidjani A, LaMarche MJ, ... ... Mohseni M, et al. Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers. Molecular Cancer Therapeutics. PMID 31439712 DOI: 10.1158/1535-7163.Mct-19-0170  0.554
2019 Lu H, Liu C, Velazquez R, Wang H, Dunkl LM, Kazic-Legueux M, Haberkorn A, Billy E, Manchado E, Brachmann SM, Moody S, Engelman JA, Hammerman PS, Caponigro G, Mohseni M, et al. SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors. Molecular Cancer Therapeutics. PMID 31068384 DOI: 10.1158/1535-7163.Mct-18-0852  0.535
2019 Sarver P, Acker M, Bagdanoff JT, Chen Z, Chen YN, Chan H, Firestone B, Fodor M, Fortanet J, Hao H, Hentemann M, Jouk A, Kato M, Koenig R, LaBonte LR, ... ... Mohseni M, et al. Correction to 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors. Journal of Medicinal Chemistry. PMID 30900883 DOI: 10.1021/Acs.Jmedchem.9B00436  0.359
2019 Sarver P, Acker MG, Bagdanoff J, Chen Z, Chen YP, Chan H, Firestone B, Fodor M, Fortanet J, Hao H, Hentemann M, Kato M, Koenig R, LaBonte LR, Liu G, ... ... Mohseni M, et al. 6-Amino-3-Methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors. Journal of Medicinal Chemistry. PMID 30688459 DOI: 10.1021/Acs.Jmedchem.8B01726  0.45
2019 Lu H, Liu C, Velazquez R, Wang H, Dunkl LM, Kazic-Legueux M, Haberkorn A, Billy E, Manchado E, Brachmann SM, Moody S, Engelman JA, Hammerman PS, Caponigro G, Mohseni M, et al. Abstract 954: SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-954  0.49
2018 Cai Z, Kotzin JJ, Ramdas B, Chen S, Nelanuthala S, Palam LR, Pandey R, Mali RS, Liu Y, Kelley MR, Sandusky G, Mohseni M, Williams A, Henao-Mejia J, Kapur R. Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis. Cell Stem Cell. 23: 833-849.e5. PMID 30526882 DOI: 10.1016/J.Stem.2018.10.013  0.589
2018 LaRochelle JR, Fodor M, Vemulapalli V, Mohseni M, Wang P, Stams T, LaMarche MJ, Chopra R, Acker MG, Blacklow SC. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. Nature Communications. 9: 4508. PMID 30375388 DOI: 10.1038/s41467-018-06823-9  0.627
2018 Karpov AS, Abrams T, Clark S, Raikar A, D'Alessio JA, Dillon MP, Gesner TG, Jones D, Lacaud M, Mallet W, Martyniuk P, Meredith E, Mohseni M, Nieto-Oberhuber CM, Palacios D, et al. Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug Conjugates. Acs Medicinal Chemistry Letters. 9: 838-842. PMID 30128077 DOI: 10.1021/Acsmedchemlett.8B00254  0.405
2018 Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, ... ... Mohseni M, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nature Medicine. PMID 29505033 DOI: 10.1038/Nm.4497  0.482
2018 Cai Z, Kotzin J, Ramdas B, Chen S, Nelanuthala S, Palam LR, Pandey R, Mali R, Liu Y, Kelley MR, Sandusky G, Mohseni M, Williams A, Henao-Mejia J, Kapur R. Downregulation of Morrbid in Tet2-Deficient Preleukemic Cells Overcomes Resistance to Inflammatory Stress and Mitigates Clonal Hematopoiesis Blood. 132: 1288-1288. DOI: 10.1182/Blood-2018-99-116703  0.6
2018 Dardaei L, Wang HQ, Singh M, Fordjour P, Yoda S, Kerr G, Liang J, Cao Y, Chen Y, Gainor J, Friboulet L, Dagogo-Jack I, Myers D, Labrot E, Ruddy D, ... ... Mohseni M, et al. Abstract A145: SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A145  0.474
2017 LaRochelle JR, Fodor M, Ellegast JM, Liu X, Vemulapalli V, Mohseni M, Stams T, Buhrlage SJ, Stegmaier K, LaMarche MJ, Acker MG, Blacklow SC. Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2. Bioorganic & Medicinal Chemistry. PMID 29089257 DOI: 10.1016/J.Bmc.2017.10.025  0.672
2017 Dardaei L, Wang HQ, Fordjour P, Singh M, Kerr G, Yoda S, Liang J, Cao Y, Chen Y, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, ... ... Mohseni M, et al. Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC) Cancer Research. 77: 1007-1007. DOI: 10.1158/1538-7445.Am2017-1007  0.53
2016 Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget. PMID 27472462 DOI: 10.18632/Oncotarget.10852  0.469
2015 Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, ... ... Mohseni M, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Science Translational Medicine. 7: 314ra185. PMID 26582900 DOI: 10.1126/Scitranslmed.Aac5272  0.461
2014 Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo FD, Gregory RI. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell. 156: 893-906. PMID 24581491 DOI: 10.1016/J.Cell.2013.12.043  0.617
2014 Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW, Walton ZE, Barrios J, Weiss DJ, Camargo FD, Wong KK, Kim CF. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. The Embo Journal. 33: 468-81. PMID 24497554 DOI: 10.1002/Embj.201386082  0.638
2014 Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, Wei C, Frazier M, Samson O, Wong KK, Wong KK, Kim C, Camargo FD. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nature Cell Biology. 16: 108-17. PMID 24362629 DOI: 10.1038/Ncb2884  0.682
2014 Mohseni M, Sun J, Lau A, Curtis S, Goldsmith J, Fox VL, Wei C, Frazier M, Samson O, Wong K, Kim C, Camargo FD. Erratum: Corrigendum: A genetic screen identies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway Nature Cell Biology. 16: 200-200. DOI: 10.1038/Ncb2912  0.615
2011 Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR, Camargo FD. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell. 144: 782-95. PMID 21376238 DOI: 10.1016/J.Cell.2011.02.031  0.647
2009 Mohseni M, Chishti AH. Regulatory models of RhoA suppression by dematin, a cytoskeletal adaptor protein. Cell Adhesion & Migration. 3: 191-4. PMID 19262171 DOI: 10.4161/Cam.3.2.7375  0.633
2009 Mohseni M, Khan A, Chishti AH. Erythrocyte Dematin Regulates Glucose Transport Via Akt Phosphorylation and 14-3-3zeta Association. Blood. 114: 1990-1990. DOI: 10.1182/Blood.V114.22.1990.1990  0.609
2008 Mohseni M, Chishti AH. The headpiece domain of dematin regulates cell shape, motility, and wound healing by modulating RhoA activation. Molecular and Cellular Biology. 28: 4712-8. PMID 18505823 DOI: 10.1128/Mcb.00237-08  0.653
2008 Khan AA, Hanada T, Mohseni M, Jeong JJ, Zeng L, Gaetani M, Li D, Reed BC, Speicher DW, Chishti AH. Dematin and adducin provide a novel link between the spectrin cytoskeleton and human erythrocyte membrane by directly interacting with glucose transporter-1. The Journal of Biological Chemistry. 283: 14600-9. PMID 18347014 DOI: 10.1074/Jbc.M707818200  0.565
2008 Mohseni M, Chishti AH. Erythrocyte dematin is a candidate gene for Marie Unna hereditary hypotrichosis and related hairloss disorders. American Journal of Hematology. 83: 430-2. PMID 18273904 DOI: 10.1002/Ajh.21153  0.533
Show low-probability matches.